OPKO Health Corp. (OPK) - Long-Term Debt to Capital Ratio

Corporate emblem and logo of OPKO Health, Inc. (OPK)

OPKO Health, Inc. (OPK) is developing a comprehensive medical service that combines pharmaceutical production with the BioReference diagnostic network. This chart from GURU.Markets shows the share price at 0.30, confirming the asset's market valuation. The company integrates treatment and testing for full patient management, although the stable B2B segment is currently suffering from declining Medicare reimbursement rates, which is negatively impacting profitability.

OPKO Health Corp. (OPK): Long-Term Debt to Equity from 07/04/2022 to 10/30/2026

Analytical breakdowns for OPKO Health, Inc.

- market price and analyst price targets:
Market Price OPKO Health Inc|OPK - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization OPKO Health, Inc.|OPK - Enterprise Value
- issuer book value statistics:
Book Value per Share OPKO Health|OPK - Company Book Value|Capitalization to Book Value Ratio opko.com|OPK - Company Total Assets
- debt and solvency information:
Total Debt to Capital OPKO Health, Inc.|OPK - Long-Term Debt to Equity|Short-Term Debt to Equity opko.com|OPK - Company Total Debt|Debts to Book Value OPKO Health, Inc.|OPK - Company Long-Term Debt|Short-Term Debt Volume OPKO Health|Interim Coverage Ratio opko.com
- net income and valuation ratios data:
OPK - Company Net Income
General company analysis:OPK (OPKO Health Inc)
Core merchandise of opko.com

OPKO Health, Inc. (OPK) revenues from genetic testing and nephrology drugs establish the foundation for long-term R&D investment. The ratio of liabilities with a maturity of over one year to total capital determines the degree of financial autonomy, where reduced reliance on borrowed funds confirms the stability of the balance sheet structure, clearly reflecting the level of long-term loans relative to equity.

Analysis of competing companies

Long-Term Liabilities to Capital Agilent Technologies, Inc. A|Long-Term Debt to Capital DGX|Illumina Platform - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital EXAS (Exact Sciences)|Long-Term Debt to Capital revvity.com RVTY|BIO - Long-Term Debt to Equity|NNNN (Anbio Biotechnology Ltd) - Long-Term Debt to Capital Ratio|SHC: Long-Term Debt to Capital|QuidelOrtho Inc. (QDEL) - Long-Term Debt to Capital|Long-Term Debt to Equity CareDx Inc|Long-Term Debt to Equity MRVI|Long-Term Debt to Equity Ratio FLGT (Fulgent Genetics)|LAB - Long-Term Liabilities to Capital|Long-Term Debt to Equity Cytek Bio CTKB|Ratio of Long-Term Indebtedness to Capital OraSure Corp (OSUR)|Exagen Diagnostics - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital mdxhealth.com MDXH|Lucid Diagnostics (LUCD) - Long-Term Debt to Equity|PRE - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Insight Molecular Diagnostics, Inc.|Long-Term Liabilities to Capital Trinity Biotech Corp TRIB|Long-Term Debt to Equity ProPhase Labs, Inc. (PRPH)|AIMD: Long-Term Liabilities to Equity|Long-Term Debt to Equity Co-Diagnostics CODX|Long-Term Debt to Capital Heart Test Laboratories, Inc. HSCS|BMRA - Long-Term Debt to Equity|Long-Term Liabilities to Capital Cardio Diagnostics|VRAX (Virax Biolabs Group) - Long-Term Debt to Equity Ratio|bluejaydx.com - Long-Term Debt to Capital Coefficient|AWH (Aspira Women's Health Inc.) - Long-Term Debt to Capital|AXDX: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital CNTG|ENZ - Long-Term Liabilities to Capital|Long-Term Debt to Capital FRES (Fresh2 Group)|Long-Term Debt to Capital Genetic Technologies Ltd GENE|ME - Long-Term Debt to Equity|PMD: Long-Term Debt to Equity